Proactive Investors - Run By Investors For Investors

Cronos stock swoons on a trio of downgrades to the cannabis-focused company

One analyst downgraded the stock to Sell, citing a 'soft start' to Canada's legal cannabis market
Hand holding up red downward arrow
Two analysts dropped the stock to Hold from Buy, and one shifted to Sell from Hold

Cronos Group Inc (TSX:CRON) (NASDAQ:CRON) shares fell Wednesday after a trio of downgrades hit the cannabis stock.

PI Financial's Jason Zandberg and Cormack’s Jesse Pytlak each rethought their bullishness on the Toronto firm, downshifting, respectively, to Neutral from Buy and to Market Perform from Speculative Buy.

Matt Bottomley of Canaccord went a step farther, cutting his rating to Sell from Hold, citing a “soft start” to Canada’s legal cannabis market.

READ: Buds & Duds: Cronos shares tumble, Newstrike Brands soars on results

The demerits come after the cannabis investment firm posted a fourth-quarter net loss of US$116 million, US$0.06 per share, on Tuesday, compared with a $0.01 profit the previous year.

The stock sank 10% to C$24.32 on the TSX and lost more than 10% to US$18.10 on the Nasdaq.

View full CRON profile View Profile

Cronos Group Inc Timeline

Related Articles

Scientist conducting work
May 19 2019
CaPre, a potent form of Omega-3, has been shown to reduce triglycerides, but also lower 'bad cholesterol' levels, and raise 'good' ones
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
Cancer cells
June 27 2018
The Nottingham-based privately-owned company has made an impressive fist of developing the OMIS (Opto-magnetic Imaging Spectroscopy) cancer detection system
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use